Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Humanwell Healthcare (Group) Co's share price is ¥17.59.
Humanwell Healthcare (Group) Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥14.72. Hence, Humanwell Healthcare (Group) Co's PS Ratio for today is 1.20.
Good Sign:
Humanwell Healthcare (Group) Co Ltd stock PS Ratio (=1.18) is close to 1-year low of 1.11.
The historical rank and industry rank for Humanwell Healthcare (Group) Co's PS Ratio or its related term are showing as below:
SHSE:600079'
s PS Ratio Range Over the Past 10 Years
Min: 0.69 Med: 1.44 Max: 2.52
Current: 1.21
During the past 13 years, Humanwell Healthcare (Group) Co's highest PS Ratio was 2.52. The lowest was 0.69. And the median was 1.44.
SHSE:600079's PS Ratio is ranked better than 71.31% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs SHSE:600079: 1.21
During the past 13 years, Humanwell Healthcare (Group) Co's highest 3-Year average Revenue per Share Growth Rate was 53.60% per year. The lowest was -3.70% per year. And the median was 16.10% per year.
Back to Basics: PS Ratio
Humanwell Healthcare (Group) Co (SHSE:600079) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Humanwell Healthcare (Group) Co PS Ratio Related Terms
Humanwell Healthcare (Group) Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Humanwell Healthcare (Group) Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humanwell Healthcare (Group) Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Humanwell Healthcare (Group) Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Humanwell Healthcare (Group) Co's PS Ratio falls into.
Humanwell Healthcare (Group) Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Humanwell Healthcare (Group) Co's Share Price of today is ¥17.59. Humanwell Healthcare (Group) Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥14.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Humanwell Healthcare (Group) Co (SHSE:600079) has a PS Ratio of 1.20 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Humanwell Healthcare (Group) Co and its competitors. This is 17% below median its historical median of 1.44. Over the past decade, Humanwell Healthcare (Group) Co's PS Ratio has ranged from 0.69 to 2.52. According to the industry distribution chart, Humanwell Healthcare (Group) Co ranks #274 out of 955 companies in the Drug Manufacturers industry, placing it in the top 28.7%.
Is Humanwell Healthcare (Group) Co's PS Ratio too high?
Humanwell Healthcare (Group) Co's current PS Ratio of 1.20 is 17% below median its 10-year median of 1.44. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 2.52. The Drug Manufacturers industry median PS Ratio is 2.33. Humanwell Healthcare (Group) Co's value of 1.20 is 48.5% below this industry median. Based on the distribution chart, Humanwell Healthcare (Group) Co ranks #274 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Humanwell Healthcare (Group) Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Humanwell Healthcare (Group) Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Humanwell Healthcare (Group) Co ranks #274 out of 955 companies for PS Ratio. This puts Humanwell Healthcare (Group) Co in the upper half of its industry. The industry median PS Ratio is 2.33. Humanwell Healthcare (Group) Co's value of 1.20 is 48.5% below this benchmark. Historically, Humanwell Healthcare (Group) Co's own PS Ratio has ranged from 0.69 to 2.52 over the past decade. While the company's 10-year median is 1.44 vs. the industry median of 2.33, Humanwell Healthcare (Group) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Humanwell Healthcare (Group) Co's current PS Ratio of 1.20 is 48.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Humanwell Healthcare (Group) Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Humanwell Healthcare (Group) Co's current PS Ratio is 1.20, which is 17% below median its own 10-year median of 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humanwell Healthcare (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co (SHSE:600079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.64, compared to a current price of ¥17.59 — trading 18.7% below its estimated fair value. The current PS Ratio is 1.20, which is 17% below median its 10-year median of 1.44 and 48.5% below the Drug Manufacturers industry median of 2.33. Humanwell Healthcare (Group) Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Humanwell Healthcare (Group) Co (SHSE:600079), the current PS Ratio is 1.20 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humanwell Healthcare (Group) Co (SHSE:600079) Overvalued in 2026?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co stock appears to be undervalued.
The current stock price of ¥17.59 is trading 18.7% below its estimated GF Value™ of ¥21.64.
GuruFocus considers Humanwell Healthcare (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600079:
PS Ratio: 1.20 (17% below median its 10-year median of 1.44)
GF Value™: ¥21.64 vs. price of ¥17.59 (18.7% below fair value)
Industry Position: 48.5% below the Drug Manufacturers median (#274 of 955)
No single metric tells the full story. See the SHSE:600079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Humanwell Healthcare (Group) Co Business Description
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
61GF Score
Get the complete analysis for SHSE:600079
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600079 has been successfully added to your 
